HER2 protein overexpression in non ‐amplified ductal carcinoma in situ: quality issue or transcription mechanisms gone awry?
This study compares HER2 immunohistochemistry (IHC) and chromogenicin situ hybridization (CISH) between admixed synchronous in situ and invasive carcinomas exhibiting an equivocal 2+ HER2 IHC score in the invasive component.This article is protected by copyright. All rights reserved.
Source: Histopathology - Category: Pathology Authors: Kathleen Lambein,
Louis Libbrecht,
Christine Galant,
Mieke R. Van Bockstal Tags: Correspondence Source Type: research
More News: Cancer & Oncology | Carcinoma | Carcinoma in Situ | DCIS (Ductal Carcinoma in Situ) | Ductal Carcinoma | Genetics | HER2 | Pathology | Study